{"name":"Vir Biotechnology, Inc.","slug":"vir-biotechnology-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQZHoxRmQtaFp2TzVIeUNUcVJhOThJZ1ZwaDRKbFNDUUc5cVQ3ekNFUFdhbUQ0b19vSFBWNEZUREpNel95ZG9Id3hFNFNuXzhjeGN2YWJlREhlUnJyenRIQnpKRXZYLU9hQmoyUzc4dURFZlY0S2FwOXFyMjc1blZLWWtVOGZPUm1rMHlDZUQ1R01CMmRyMW84dkRVbU9SellCX2Ztbw?oc=5","date":"2026-02-25","type":"deal","source":"The Pharma Letter","summary":"Vir Biotechnology leaps on news of Astellas collaboration - The Pharma Letter","headline":"Vir Biotechnology leaps on news of Astellas collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSTljVXdEZDFkXzFGMnpDTVZLaEhtRFlic0NKbnhWcUtQTXBnMTZ6QW1JNzRIUmxqZ1RMTXJVS1BXSkliMUFIQzcxREpha3VEczZhWkp1WUFXRkRjRDliOU9LZnduUVlPN2dzU3N2WF9lYVp3Z29odGY1VFBEbDhDMmpDTWo2YlBQelZ5cWh0Q1phUDZycUhqcmZPdlBWZThLVVFoeTFHbHFyQmdoWTRpa3BQaUpYbGNfWm9fOVJkSDNQUUk?oc=5","date":"2026-02-24","type":"deal","source":"Pharmaceutical Executive","summary":"Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN - Pharmaceutical Executive","headline":"Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-X","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPU3BRY1R2THk5aF9lQnZaTGsyTHpwVFU1NnhtYVJTV3R2X3ZPY0ZjRzJieGxkb3lhRmVlMFQ2TU1feGNkZ2Q2THpzWlhTdmNNMFVySHdJWVl3MlYxQm0yc3Yxbk5ta1hBVS1qOWVkT3dQdUVlOU1hekVxc1VicEppSWNQQm9vSGtpN1MzdGZsZ21lRkp1Zzc3czJrTEJ4T2RSQ1ZnU2N3a0s2Vzg?oc=5","date":"2026-02-24","type":"deal","source":"Contract Pharma","summary":"Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500 - Contract Pharma","headline":"Astellas Pharma, Vir Biotechnology Partner to Advance VIR-5500","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5","date":"2026-02-24","type":"pipeline","source":"Barron's","summary":"This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug - Barron's","headline":"This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOdEtJM0MzM3pFMzJyeGVoLTBld2pCZGJaR1kwZmtIcW9tOTBiOGZxNi1mVG5hdmRmMzgyYV9KUFRVMndwYWxGWEhZMFBnLWlpcjBUcTE3Y1R1NWo0UDkxM3ZkMnh2aDYwNUdlVERGU3UzaWs5aVMxUTNDZXJTSHdYZlhjQzBQcVU0cGRqbzBCendkQXNKaS04TjBseW95UW81SDlvZ1YxV0lMcjAyRVljVl9kMTV1TVhY?oc=5","date":"2026-02-24","type":"trial","source":"Seeking Alpha","summary":"Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish (VIR) - Seeking Alpha","headline":"Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish (VIR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNSC1QUUplNXdLTS1JYXlmY29PbzQ5dGtHbUl4TTlpRXk1M1pqQzVVaXAtMjEyWGZZTHRQTFpnYVp1bHFUaWxOOGRRRXJZc3ZseHBEbkNkbFR0U1F5ZmVNbERHU3M4Q0tTcmhpUDcyeHNYWkNRYWc5dXNUa0ZSTFhFUmlndlFoYnNVTURYdFJMZXRvR3RSMXllTDBBWlhVSUtmbklR?oc=5","date":"2026-02-24","type":"trial","source":"BioPharma Dive","summary":"Vir climbs on Astellas deal, study results for ‘masked’ T cell engager - BioPharma Dive","headline":"Vir climbs on Astellas deal, study results for ‘masked’ T cell engager","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPU0ZkR2NXMktwRkZyRnpuTExuNE1zNjRpSmJzQzB0N0NITksxdkU1VnRlZWlxX3pBMjZqdE8yZzJaNDBBdTR6d0g5ekc3OENDeHY5TExNZ3pmOXdPenU0S3VveW9YUm1LRHluRmRHVHhCRFBfNlBzc3lsV3pDcWJnczFuNUc5c0l6Q0Y4eHgwTU8yU0dsRHlXc1lOMGc5U21OMHFXZWJSU0VrSF94SktIMGtvLXY2NTB2cWZ5OFczd0QtNUhvUDZmM1RueVZxR21jaTZlTkppdGRXWHVBWEItNUo2Vjl6T1JuRDJoRkJVUGVEWGRRNU9HUUFTdEZWcFdqa0ppWVM0OG15VmZxc29TeU1DRnNwd1lJSjdIMWJtakpHSkg5QmRoaUxaZS1udnVwZjJkQklTRjg5UldiY2diSEtuVHJrVXcyT2E2TlpoYXYzREZM?oc=5","date":"2026-02-23","type":"deal","source":"PR Newswire","summary":"Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - PR Newswire","headline":"Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNNGw0bjQ3U3JNcUpkU0FVc1FQcTQ5eXFIT2F6OEdiSmV0aXU1NEc1YnZIRkltVjg2eVRUbjJKN2ltTFhuVXpyMWtaRUExaGRpcW9jLVlNenhmQnU4UTAyVXl1OXF0TEljeFB4WW9QNzd5Y3B6eTFVdURlRmIyUzFnbVBqU05tQ056ejYwVFJTYy1vamd5NUdtbFltTk5qQ2RnZG9iS1hzRG5nOHFfb0V6OTlfdHh2dDA?oc=5","date":"2026-02-23","type":"pipeline","source":"Stock Titan","summary":"Prostate cancer pact, 88% hepatitis delta response, cash runway to 2028 at Vir - Stock Titan","headline":"Prostate cancer pact, 88% hepatitis delta response, cash runway to 2028 at Vir","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxNR2hlU0kyaUcxREVxMFRtM1hUYmpFODJnNTNPRmplTHl2My1yeHlLNkdVWGo5cEdGM2ZzcTBBd05Lb09YOU9vN2N6MklpdF83d0VQeGVPcHliRWwxM1R4bHZoSzlDNjdWa1lmN1JKQ1M5Ny10dmotbnBhT19nYW84bjhlUVBkMjgzaVZDZF9LWkRLbXRfYWlVTzJtVTlBQ0ZYOU5ZelNfRUhMNWRyRUt1UWdSZjMzRzNSazhUX0phNjRmZEhPZnNoQWhWME10X19nNElxUkVVRHR1ckUzelFjRV93?oc=5","date":"2026-02-23","type":"pipeline","source":"reuters.com","summary":"Astellas collaborates with Vir to develop its experimental prostate cancer drug - reuters.com","headline":"Astellas collaborates with Vir to develop its experimental prostate cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQVlp1WDg1YkJURXBGd0Z4d2w0Q3h4bWs0dVBfZ2Jvd1VURWUyNURkOUFDUXZrU2pFb01taWFaNUoxR3NCc1k1a3hfcm1faTRkZ1NhMUE5SHNUVks0X1k3U0Fpd3FNM2NrMVhYN1lfVUNjMmhqUzlXeHpTSW1IZXBfc0dqQlZzRHdmakNiUTUyUHFCblpsMFBWWUpmOGVkVExNOWV2WFVWdXE?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Norgine gets in on Vir's hepatitis D program with €550M European licensing pact - Fierce Biotech","headline":"Norgine gets in on Vir's hepatitis D program with €550M European licensing pact","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQaUptdWdONUh6alFuOURaRURWQk5pVVJUWjFTd1BEOENrRDBNVWhTSl9WcTU1dnFBOGFVdk1FTm1pR1gwOUt3OHdxeG81ckdUb2R4a0djd1M2TkNkeXlYVEo5ZUVnZTJKSEJiZlI2MWZXVDZuV3J2WnM4OE1xbUdUR25HQkRKWlpZenRaZVQ0eHl6Y3dGU2ZSQnVqaHRVY04xcFBselJIdVc?oc=5","date":"2025-12-17","type":"pipeline","source":"Latham & Watkins LLP","summary":"Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP","headline":"Latham Advises Norgine on Exclusive Licensing Agreement With Vir Biotechnology - Latham & Watkins LLP","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-16","type":"deal","source":"Business Wire","summary":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECL","headline":"Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, ","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}